



FINAL

Gynecologic Cancer InterGroup (GCI)

Cervix Cancer Committee

Thursday, June 1, 2017, 3:00 pm – 4:30 pm

LaSalle I Room, DoubleTree Hotel, Chicago

Chair: Brad Monk Co-Chair: Antonio Casado

Harmonization Liaisons: Stonebraker/Keller (Ops), Reuss (Stats)

AGENDA

Please sign Attendance Forms

WELCOME & INTRODUCTIONS & COI declarations

Monk

Approval of report/minutes Oct. 2016 (posted on GCI website)

Motion: _____ Seconded: _____

PUBLISHED TRIALS:

CLOSED TRIALS:

ONGOING TRIALS:

- I. EORTC
 - a. EORTC 55994: NAC + RH vs CCRT Casado
 - b. EORTC-GCG: Transgene + anti-PD-1 antibody Scholl
- II. KGOG
 - a. KGOG 0801/GOG 263 Ryu
 - b. TACO Ryu
- III. RTOG (NRG)
 - a. 0724 Small
 - b. RTOG Hypofractionation Small/Gaffney
- IV. ANZGOG
 - a. OUTBACK/NRG 0274 Mileskin
- V. MRC-NCRI
 - a. INTERLACE McCormack

VI.	CCTG (NCIC)	
	a. SHAPE/CX.5	Plante
	b. Neo-adj. CT & fertility sparing surgery (stage IBI)	Plante
VII.	G-GOC	
	a. LiLACS	Ramirez
	b. ConCerv	Ramirez
	c. LACC	Ramirez
VIII.	GOG (NRG)	
	a. 278	Monk
	b. 279	Monk
	c. AIM2CERV	Monk
IX.	GINECO	
	a. SENTICOL III	Lecuru
X.	DGOG	
	a. GROINSS-V II	Bekkers

NEW/PROPOSED OR DEVELOPING CONCEPTS :

1)

DISCUSSION

ADJOURN